Related Experiment Video

Updated: Sep 5, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.4K

Effects of Sacubitril/Valsartan on the Renal Resistance Index

Margherita Ilaria Gioia1,2, Giuseppe Parisi2,3, Dario Grande2,3

  • 1Cardiology Unit, Perrino Hospital, 72100 Brindisi, Italy.

Journal of Clinical Medicine
|July 9, 2022
PubMed

Insights

Sacubitril/valsartan improved heart function and reduced renal resistance in heart failure patients. This treatment benefits cardiorenal syndrome by enhancing renal perfusion.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Sacubitril/valsartan is vital for heart failure with reduced ejection fraction (HFrEF) patients.
  • Evidence suggests sacubitril/valsartan may preserve renal function.
  • Cardiorenal syndrome necessitates further investigation into sacubitril/valsartan's renal effects.

Purpose of the Study:

  • To evaluate sacubitril/valsartan's impact on renal resistance index (RRI) in HFrEF patients.
  • To clarify sacubitril/valsartan's role in managing cardiorenal syndrome.

Main Methods:

  • Assessed RRI using renal echo-color Doppler in HFrEF patients before and after sacubitril/valsartan treatment.
  • Evaluated changes in left and right ventricular function parameters.
  • Monitored creatinine and estimated glomerular filtration rate.

Main Results:

  • Sacubitril/valsartan treatment significantly improved left ventricular ejection fraction and reduced ventricular volumes.
  • A significant decrease in RRI was observed post-treatment.
  • No correlation found between cardiac function improvements and RRI changes.

Conclusions:

  • Sacubitril/valsartan improves left ventricular function and renal perfusion in HFrEF patients.
  • The drug decreases renal resistance, positively impacting cardiorenal syndrome.
  • These findings clarify sacubitril/valsartan's beneficial effects on cardiorenal interactions.
Abstract

Keywords:
angiotensin receptor–neprilysin inhibitorscardiorenal syndromeheart failure with reduced ejection fractionrenal resistance indexreverse cardiac remodeling

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.0K
Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

12.1K

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
904
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
503
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
812
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
860
Vascular Resistance01:20

Vascular Resistance

Vascular resistance is a critical concept in understanding blood flow dynamics in the circulatory system. It refers to the resistance that blood encounters as it flows through the blood vessels. This resistance is a key factor in determining blood pressure and cardiac workload.
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...
5.1K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23